Form 4: Entrada Therapeutics CFO Kory James Wentworth Reports Stock Transactions

Chief Financial Officer of Entrada Therapeutics, Kory James Wentworth, reports acquisition of restricted stock units and stock options, as well as a sale of shares to cover tax obligations.

Summary

• Kory James Wentworth, CFO of Entrada Therapeutics, reported transactions involving the company's stock.
• On March 1, 2025, Wentworth acquired 42,400 shares of common stock in the form of restricted stock units (RSUs) and 63,300 stock options.
• The RSUs vest in four equal installments on March 1st of 2026, 2027, 2028 and 2029.
• The stock options vest 25% on March 1, 2026, and the remaining 75% vest in 36 equal monthly installments thereafter, fully vesting on March 1, 2029.
• On March 3, 2025, Wentworth sold 4,929 shares of common stock at a weighted average price of $11.6786 to cover tax withholding obligations related to the vesting of previously granted RSUs.
• Following these transactions, Wentworth beneficially owns 111,320 shares of common stock and 63,300 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The grants are a positive sign of aligning management with shareholders, but the sale to cover taxes is a minor negative.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with the long-term success of the company.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces the CFO's direct stake in the company.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for executives in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules of 3-4 years are typical for such grants, incentivizing long-term commitment to the company.
• Sales of shares to cover tax obligations are also a common occurrence among executives receiving equity compensation.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The equity grants incentivize the CFO to work towards the long-term success of the company, benefiting shareholders and employees.

Key Dates

Keywords

Entrada Therapeutics, Kory James Wentworth, stock options, RSUs, Form 4, insider trading, CFO, stock sale, vesting